Tech Company Financing Transactions
Tolero Pharmaceuticals Funding Round
Fred Alger Management participated in a $8 million Series B funding round for Tolero Pharmaceuticals. The round closed on 11/5/2014.
Transaction Overview
Company Name
Announced On
11/5/2014
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series B
Investors
Fred Alger Management (Lead Investor)
Proceeds Purpose
Proceeds will support the further development and commercialization of Tolero's lead program, alvocidib, which is being developed for the treatment of acute myeloid leukemia (AML) and the ongoing advancement of its preclinical pipeline. Tolero plans to initiate Phase 3 clinical trials of alvocidib in patients with AML and clinical trials of two of its preclinical programs in 2015.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3900 N Traverse Mountain Blvd. 100
Lehi, UT 84043
USA
Lehi, UT 84043
USA
Phone
Website
Email Address
Not Recorded
Overview
Tolero Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to alleviating human suffering through the discovery and development of novel therapeutics to treat cancer and other serious human diseases. Our pipeline targets important biological drivers of blood disorders to treat leukemias and anemia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Bearss
Chief Financial Officer
David Sampson
Chief Operating Officer
Michael McCullar
Vice President
Kotaro Hirota
VP - Bus. Development
Katsumi Tanaka
VP - Bus. Development
Steven Warner
VP - R & D
Stephen Anthony
VP - Regulatory Affairs
Michael Bernstein
Browse more venture capital transactions:
Prev: 11/5/2014: Eaze venture capital transaction
Next: 11/5/2014: Pendo venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs